Amica Mutual Insurance Co. reduced its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 31.1% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 66,435 shares of the medical equipment provider’s stock after selling 30,030 shares during the period. Amica Mutual Insurance Co.’s holdings in Boston Scientific Corporation were worth $1,938,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of BSX. Janus Henderson Group PLC boosted its position in shares of Boston Scientific Corporation by 22,491.6% during the 2nd quarter. Janus Henderson Group PLC now owns 38,862,599 shares of the medical equipment provider’s stock valued at $1,077,270,000 after acquiring an additional 38,690,577 shares in the last quarter. Jennison Associates LLC boosted its position in shares of Boston Scientific Corporation by 405.3% during the 2nd quarter. Jennison Associates LLC now owns 10,639,290 shares of the medical equipment provider’s stock valued at $294,921,000 after acquiring an additional 8,533,655 shares in the last quarter. BlackRock Inc. boosted its position in shares of Boston Scientific Corporation by 4.6% during the 2nd quarter. BlackRock Inc. now owns 100,184,511 shares of the medical equipment provider’s stock valued at $2,777,113,000 after acquiring an additional 4,439,966 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. boosted its position in shares of Boston Scientific Corporation by 35,016.2% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 3,042,464 shares of the medical equipment provider’s stock valued at $84,337,000 after acquiring an additional 3,033,800 shares in the last quarter. Finally, Prudential Financial Inc. boosted its position in shares of Boston Scientific Corporation by 149.1% during the 3rd quarter. Prudential Financial Inc. now owns 4,762,674 shares of the medical equipment provider’s stock valued at $138,928,000 after acquiring an additional 2,850,630 shares in the last quarter. Institutional investors and hedge funds own 90.68% of the company’s stock.

In related news, EVP Timothy A. Pratt sold 10,104 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $27.46, for a total transaction of $277,455.84. Following the completion of the sale, the executive vice president now directly owns 185,742 shares of the company’s stock, valued at $5,100,475.32. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Michael P. Phalen sold 15,500 shares of the business’s stock in a transaction that occurred on Tuesday, August 29th. The stock was sold at an average price of $26.87, for a total transaction of $416,485.00. The disclosure for this sale can be found here. Insiders have sold 508,864 shares of company stock worth $14,581,669 over the last quarter. 0.74% of the stock is owned by company insiders.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/11/24/amica-mutual-insurance-co-sells-30030-shares-of-boston-scientific-corporation-bsx.html.

Boston Scientific Corporation (BSX) opened at $28.47 on Friday. Boston Scientific Corporation has a 12-month low of $19.67 and a 12-month high of $29.93. The stock has a market cap of $39,094.89, a P/E ratio of 23.34, a PEG ratio of 2.20 and a beta of 1.00. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.50 and a current ratio of 0.72.

Boston Scientific Corporation (NYSE:BSX) last announced its earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.31. Boston Scientific Corporation had a net margin of 9.55% and a return on equity of 23.60%. The company had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.21 billion. During the same period in the prior year, the business earned $0.27 earnings per share. Boston Scientific Corporation’s quarterly revenue was up 5.6% on a year-over-year basis. research analysts anticipate that Boston Scientific Corporation will post 1.25 EPS for the current fiscal year.

A number of research firms have commented on BSX. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Boston Scientific Corporation in a research report on Wednesday, August 9th. Cowen Inc restated a “buy” rating and issued a $32.00 price target (up from $31.00) on shares of Boston Scientific Corporation in a research report on Friday, July 28th. Stifel Nicolaus restated a “buy” rating and issued a $32.00 price target on shares of Boston Scientific Corporation in a research report on Monday, September 25th. Zacks Investment Research upgraded shares of Boston Scientific Corporation from a “sell” rating to a “hold” rating in a research report on Monday, July 31st. Finally, UBS AG restated a “buy” rating and issued a $31.00 price target (up from $30.00) on shares of Boston Scientific Corporation in a research report on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $30.77.

Boston Scientific Corporation Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.